-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
ZP1846
Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.
At Zealand, we have applied our SIP®-technology and know-how related to reengineering and stabilization of peptides and produced a series of novel GLP-2 peptide analogues with enhanced stability and efficacy. In pre-clinical pharmacological studies, ZP1846 consistently stimulates growth of the small intestinal mucosa and decreases the incidence and severity of Chemotherapy-Induced Diarrhea (CID).
It is anticipated that use of ZP1846 may ameliorate or prevent the destructive effects of chemotherapy on the small intestine and thereby reduce the incidence of diarrhea. Based on the Company’s pre-clinical data a phase I clinical evaluation in healthy volunteers was initiated in September 2007 in the United States.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.